{"denoms":[{"counts":[{"groupId":"BG000","value":"66"},{"groupId":"BG001","value":"64"},{"groupId":"BG002","value":"130"}],"units":"Participants"}],"groups":[{"description":"INDUCTION THERAPY:\n\nPatients receive amifostine IV over 3-5 minutes on days -3 and -2 followed by high-dose melphalan IV over 15-30 minutes on day 2.\n\nAUTOLOGOUS OR SYNGENEIC PBSCT: At least 20 hours after completion of melphalan, patients undergo autologous or syngeneic PBSCT on day 0.\n\nPatients undergo restaging of the disease between days 80-90. Patients with progressive disease are removed from the study. Patients who achieve a CR or near-CR can proceed to optional maintenance therapy. Patients who do not achieve a CR or near-CR may undergo additional induction therapy as in arm I followed by a second autologous or syngeneic PBSCT.\n\nPatients again undergo restaging of the disease 80-90 days later. Patients with progressive disease are removed from the study. Patients without progressive disease can proceed to maintenance therapy.","id":"BG000","title":"Arm I (High Dose Melphalan, Amifostine Trihydrate, Transplant)"},{"description":"INDUCTION THERAPY:\n\nPatients receive amifostine as in arm I and melphalan as in arm I at a lower dose.\n\nAUTOLOGOUS OR SYNGENEIC PBSCT: At least 20 hours after completion of melphalan, patients undergo autologous or syngeneic PBSCT on day 0.\n\nPatients undergo restaging of the disease between days 80-90. Patients with progressive disease are removed from the study. Patients who achieve a CR or near-CR can proceed to optional maintenance therapy. Patients who do not achieve a CR or near-CR may undergo additional induction therapy as in arm I followed by a second autologous or syngeneic PBSCT.\n\nPatients again undergo restaging of the disease 80-90 days later. Patients with progressive disease are removed from the study. Patients without progressive disease can proceed to maintenance therapy.","id":"BG001","title":"Arm II (Low Dose Melphalan, Amifostine Trihydrate, Transplant)"},{"description":"Total of all reporting groups","id":"BG002","title":"Total"}],"measures":[{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"0"},{"groupId":"BG001","value":"0"},{"groupId":"BG002","value":"0"}],"title":"<=18 years"},{"measurements":[{"groupId":"BG000","value":"57"},{"groupId":"BG001","value":"55"},{"groupId":"BG002","value":"112"}],"title":"Between 18 and 65 years"},{"measurements":[{"groupId":"BG000","value":"9"},{"groupId":"BG001","value":"9"},{"groupId":"BG002","value":"18"}],"title":">=65 years"}]}],"paramType":"COUNT_OF_PARTICIPANTS","title":"Age, Categorical","unitOfMeasure":"Participants"},{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"23"},{"groupId":"BG001","value":"23"},{"groupId":"BG002","value":"46"}],"title":"Female"},{"measurements":[{"groupId":"BG000","value":"43"},{"groupId":"BG001","value":"41"},{"groupId":"BG002","value":"84"}],"title":"Male"}]}],"paramType":"COUNT_OF_PARTICIPANTS","title":"Sex: Female, Male","unitOfMeasure":"Participants"},{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"66"},{"groupId":"BG001","value":"64"},{"groupId":"BG002","value":"130"}]}],"title":"United States"}],"paramType":"NUMBER","title":"Region of Enrollment","unitOfMeasure":"participants"}]}